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Abstract
 
Interleukin 13 receptor 
 
 
 
2 (IL-13R
 
 
 
2) chain is highly expressed on some tumor cell lines and
primary cell cultures. This receptor chain plays an important role in ligand binding and inter-
nalization. To determine the functional significance of overexpression of this chain, we stably
transfected IL-13R
 
 
 
2 chain in human breast (MDA-MB-231) and pancreatic (PANC-1) can-
cer cell lines that naturally do not express this chain. There was no difference in growth be-
tween vector only transfected and IL-13R
 
 
 
2 chain transfected cells in vitro. However, surpris-
ingly, in immunodeficient mice, tumorigenicity was profoundly inhibited in IL-13R
 
 
 
2 chain
overexpressing tumors. Because breast tumors that grew later showed loss of IL-13R
 
 
 
2 gene
expression, lack of tumorigenicity correlated positively with IL-13R
 
 
 
2 chain expression. In-
flammatory cells including neutrophils and macrophages were identified in IL-13R
 
 
 
2 overex-
pressing regressing tumors and neutrophils were found to produce IL-13. IL-13 showed a
modest antitumor activity to IL-13R
 
 
 
2 chain overexpressing tumors in vitro and in vivo. Fur-
thermore, IL-13R
 
 
 
2 chain overexpressing tumors constitutively produced IL-8 that has been
shown to have antitumor effect. These results establish a novel function of a cytokine receptor
chain and further suggest that the presence of this chain on tumor cells by itself may play a key
role in tumorigenicity.
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Introduction
 
IL-13 is a Th2 cell–derived pleiotropic immune regulatory
cytokine (1). It has predominant biological activities on B
cells and monocytes. In recent years, the receptors for IL-13
(IL-13R) have been extensively characterized. We have
demonstrated that IL-13R may exist as three different
forms in different cell types (2–7). Two different chains of
 
the IL-13R, IL-13R
 
 
 
1 (also known as IL-13R
 
  
 
) and
IL-13R
 
 
 
2 (also known as IL-13R
 
 
 
) have been cloned.
The murine and human IL-13R
 
 
 
1 chain was cloned first
(8, 9). This chain binds IL-13 at low level but when coupled
 
with IL-4R
 
 
 
 chain (also known as IL-4R
 
 
 
) binds IL-13
with high affinity and mediates IL-13–induced signaling (8–
10). The second chain of IL-13R, IL-13R
 
 
 
2 was cloned
from a human renal cell carcinoma cell line (Caki-1). This
chain has 50% homology to IL-5R at the DNA level, has a
 
short intracellular domain, and binds IL-13 with 
 
 
 
50 times
higher affinity than IL-13R
 
 
 
1 chain (11, 12).
 
We and others have reported that IL-13R
 
 
 
2 chain is
expressed on many human cancer cell lines and primary
cell cultures including glioblastoma, AIDS-associated Ka-
posi’s sarcoma, ovarian carcinoma, renal cell carcinoma
(13–16), and fibroblast cell lines (6). Interestingly, this re-
ceptor chain does not seem to be present or present at ex-
tremely low level in normal endothelial cells, immune
cells, or certain types of cancer cell lines as assessed by RT-
PCR analysis (12–15). The reason for difference in the ex-
pression is unknown; however, it is predicted that some
correlation between the presence of IL-13R
 
 
 
2 chain and
tumor biology must exist. More recently, we have dem-
onstrated that IL-13R
 
 
 
2 chain plays an important role in
IL-13 binding and internalization (17–19). Although the
function of IL-13R
 
 
 
2 chain is being unraveled, it is still
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not known why this receptor chain is expressed on the sur-
face of only certain tumor cell lines. Numerous studies in
the literature suggest that gene transfer of cytokine or
growth factors in tumor cells can inhibit tumorigenicity of
murine or human tumors in experimental animals (20–25).
In most studies, resident immune cells seemed to play a
major role in the loss of tumorigenesis in vivo (20, 21, 23–
26). However, several studies have reported that in addi-
tion to immune mechanism, in some situations, inflammatory
cells such as eosinophils and macrophages play a dominant
role in the control of tumor growth (24, 25). Although the
mechanism of tumor growth control by inflammatory cells
is not completely clear, the growth factor(s) or chemo-
kine(s) produced by these cells may play some role in this
process (26–28). One of the chemokine, IL-8, has been
shown to play a major role in the control of tumorigenesis
most likely through regulation of angiogenesis in develop-
ing tumor (20, 21, 26). Despite extensive studies on the
role of growth factors, cytokines, and chemokines on tu-
morigenesis, the role of receptors for these factors has not
been extensively studied.
In this study, we have examined the functional signifi-
cance of IL-13R
 
 
 
2 chain in two tumor models. We stably
transfected human breast cancer cell line, MDA-MB-231
and pancreatic cancer cell line, PANC-1 with IL-13R
 
 
 
2
chain. Various clones of these cell lines were assessed for
IL-13 receptor expression in vitro and in vivo, and the ef-
fect of IL-13R
 
 
 
2 chain on tumorigenicity of these two tu-
morigenic tumor cell lines was investigated. To our sur-
prise, we found that the overexpression of IL-13R
 
 
 
2 chain
profoundly inhibited tumor development in immunodefi-
cient animals. The mechanism of tumor regression in these
two tumor models has been investigated.
 
Materials and Methods
 
Recombinant Cytokine, Toxin, and Cell Lines.
 
Recombinant
human IL-4 and IL-13 were produced and purified to homoge-
neity in our laboratory (29). Recombinant IL-13-
 
Pseudomonas ex-
otoxin
 
 A (PE)
 
*
 
38QQR was also produced and purified in our lab-
oratory (30, 31). Human breast cancer (MDA-MB-231) and
pancreatic cancer (PANC-1) cell lines were purchased from the
American Type Culture Collection. Cells were cultured in
RPMI 1640 (MDA-MB-231) or DMEM (PANC-1) containing
10% FBS (Biowhittaker), 1 mM Hepes, 1 mM 
 
L
 
-glutamine, 100
 
 
 
g/ml penicillin, and 100 
 
 
 
g/ml streptomycin (Biowhittaker).
 
Stable Transfection and Selection.
 
cDNA encoding human IL-
13R
 
 
 
2 chain was cloned into pME18S mammalian expression
vector (11, 32). Plasmid DNA (12 
 
 
 
g/100-mm culture dish) was
cotransfected with 1.2 
 
 
 
g of pPUR selection vector (CLON-
TECH) into semiconfluent cells using GenePORTER transfec-
tion reagent (Gene Therapy Systems) according to the manufac-
turer’s instructions. Briefly, cells (2 
 
 
 
 10
 
6
 
 cells per 100-mm dish)
were incubated with the DNA-GenePORTER mixture for 5 h
in DMEM followed by 20-h incubation in fresh DMEM con-
taining 20% FBS and additional 24 h in medium with 10% FBS.
At 48 h after the start of transfection, cells were trypsinized and
 
cultured in selection medium that contained 1 
 
 
 
g/ml of puro-
mycin (CLONTECH). Cells were maintained for 4 wk in the
same medium, which was replaced every 3 d. Resistant clones
isolated with the cloning cylinder (Bel-Art Products) were char-
acterized for IL-13R
 
 
 
2 chain expression by RT-PCR and ra-
dioreceptor binding assays. Finally, three IL-13R
 
 
 
2-overexpress-
ing clones (termed 
 
 
 
2 clone 1, 2, and 3) were selected for further
analysis. The vector control (mock) transfected cell lines were
used for comparison with IL-13R
 
 
 
2 transfected cells. To reduce
antibiotic side effects, puromycin was removed at least 14 d be-
fore experiments were performed.
 
RT-PCR.
 
To detect the mRNA expression in cells, total
RNA was isolated using TRIZOL reagent (Life Technologies),
then RT-PCR was performed using specific primers as described
previously (13, 33).
 
Radioreceptor Binding Assays.
 
Recombinant human IL-13 was
labeled with 
 
125
 
[I] (Amersham Pharmacia Biotech) using IODO-
GEN reagent (Pierce Chemical Co.) as described previously (34).
The specific activity of the radio-labeled cytokines was estimated
to be 12.7 
 
 
 
Ci/
 
 
 
g of protein. For binding experiments, 5 
 
 
 
 10
 
5
 
cells in 100 
 
 
 
l binding buffer (RPMI 1640 containing 0.2%
human serum albumin and 10 mM Hepes) were incubated
with 200 pM 
 
125
 
[I]-IL-13 with or without various concentrations
(10 pM to 100 nM) of unlabeled IL-13 at 4
 
 
 
C for 2 h. Cell-
bound 
 
125
 
[I]-IL-13 was separated from unbound by centrifugation
through a phthalate oil gradient and radioactivity was determined
with a 
 
 
 
 counter (Wallac). In some experiments, the number of
IL-13Rs and binding affinities were calculated using the
LIGAND program (35).
 
Protein Synthesis Inhibition Assay.
 
The cytotoxic activity of
IL-13 toxin was tested as described previously (36). Typically, 10
 
4
 
cells were cultured in leucine-free medium with or without vari-
ous concentrations of IL-13-PE38QQR for 20–22 h at 37
 
 
 
C.
Then 1 
 
 
 
Ci of [
 
3
 
H]leucine (NEN Research Products) was added
to each well and incubated for an additional 4 h. Cells were har-
vested and radioactivity incorporated into cells was measured by a
 
 
 
 plate counter (Wallac).
 
Animal Studies.
 
Athymic nude mice 4 wk old (
 
 
 
20 g in
body weight) were obtained from Frederick Cancer Center Ani-
mal Facilities (National Cancer Institute). Animal care was in ac-
cordance with the guidelines of NIH Animal Research Advisory
Committee. Human breast and pancreatic tumor models were es-
tablished in the nude mice by subcutaneous injection into the
flank. Vector alone and IL-13R
 
 
 
2 chain cDNA transfected tu-
mor cells were 5 
 
 
 
 10
 
6
 
 MDA-MB-231 or 4 
 
 
 
 10
 
6
 
 PANC-1 cells
in 150 
 
 
 
l of PBS plus 0.2% human serum albumin. Palpable tu-
mors developed within 3–4 d. Tumors were measured by Ver-
nier calipers. In general, five mice were used for each group. In
some experiments, mice were injected with 1 
 
 
 
g of IL-13 intra-
tumorally or 0.1 mg of Gr-1 (rat anti–mouse granulocytes anti-
body; Cedarlane) intraperitoneally.
 
Histological Analysis.
 
Tissues at the site of tumor injection
were embedded in OCT compound (Miles) and snap frozen by
liquid nitrogen. 5-
 
 
 
 cryostat sections were fixed in 90% ethyl al-
cohol and stained with hematoxylin and eosin.
 
Immunofluorescence Assay.
 
Sections (5 
 
 
 
m) were prepared and
stained for neutrophils (Gr-1; BD PharMingen), macrophage
(Mac-3; BD PharMingen), or IL-13 (C-19; Santa Cruz Biotech-
nology, Inc.). Isotype control Abs was used for each correspond-
ing Ab. Slides were fixed in acetone at 
 
 
 
20
 
 
 
C for 5 min and air
dried. Nonspecific binding was blocked by treatment with 10%
serum (goat or rat) for 1 h followed by incubation with Ab or
isotype control. Sections were subsequently incubated for 1 h
 
*
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Pseudomonas
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with secondary Ab that had either tetramethylrhodamine
isothiocyanate or FITC tag. After three washes with PBS, slides
were dried and layered with Vectashield antifluorescence fading
mounting medium (Vector Laboratories) and a coverslip. The
slides were viewed in a Nikon fluorescence microscope using
appropriate filters.
 
Clonogenic Assay.
 
The in vitro antitumor activity of IL-13 on
MDA-MB-231 and PANC-1 cells transfected with IL-13R
 
 
 
2
chain or vector only (mock control) was determined by a colony-
forming assay as described previously (18).
 
ELISA for Human IL-8 Expression.
 
The level of IL-8 protein
in culture supernatants was determined by using a quantitative
immunometric sandwich enzyme immunoassay (ELISA) kit
(Human IL-8/NAP-1 immunoassay kit; BioSource Interna-
tional). The O.D. of the test sample was compared with the
standard curve.
 
Results
 
IL-13R
 
 
 
2 Expression in MDA-MB-231 and PANC-1
Cell Lines.
 
To determine the expression of IL-13R in
MDA-MB-231 and PANC-1 cell lines, we first examined
the mRNA expression of IL-13R components, IL-13R
 
 
 
2
and IL -13R
 
 
 
1 chains by RT-PCR. As shown in Fig. 1,
mRNA for IL-13R
 
 
 
1 chain was present in both cell lines,
however they did not express IL-13R
 
 
 
2 mRNA. In stably
transfected cell lines, IL-13R
 
 
 
2 chain expression was con-
firmed as these clones expressed abundant mRNA for this
chain. PM-RCC cells that express IL-13R
 
 
 
2 and IL-
13R
 
 
 
1 mRNA served as a positive control (13).
 
IL-13 Binding Sites on MDA-MB-231 and PANC-1 Cells
Increased After Gene Transfer of IL-13R
 
 
 
2 Chain.
 
Then we
determined the expression and binding affinity of IL-13R
on MDA-MB-231 and PANC-1 cell lines by 
 
125
 
[I]-IL-13
binding assays. As shown in Fig. 2 A, vector only trans-
fected control cells do not express IL-13R
 
 
 
2 chain and
consequently show minimal binding to 
 
125
 
[I]-IL-13. How-
ever, stable clones transfected with IL-13R
 
 
 
2 chain
showed highly increased 
 
125
 
[I]-IL-13 binding activity. This
 
binding activity was displaced by excess of unlabeled IL-13.
Because IL-13R and IL-4R share two chains with each
other, we also examined whether IL-4 can displace IL-13
binding in MDA-MB-231 and PANC-1 cells transfected
with IL-13R
 
 2 chain (7, 32, 37). As shown in Fig. 2 A, IL-4
showed only a little displacement of 125[I]-IL-13 binding.
These findings indicate that IL-13R 2 chain transfected
MDA-MB-231 and PANC-1 cells form a type I IL-13 re-
ceptors where IL-13R 2, IL-13R 1, and IL-4R  chains
coexist (2, 6, 7, 13). To further characterize the IL-13R in
IL-13R 2 chain transfected cells, we performed Scatchard
analysis using MDA-MB-231 2 clone 3 and PANC-1 2
clone 2 (Fig. 2 B and C). Both clone cells bound IL-13 in a
concentration-dependent manner. Scatchard analysis of the
binding data showed a single binding site receptor with a Kd
value of 1.24 nM (MDA-MB-231 2 clone 3) and 1.39 nM
(PANC-1 2 clone 2). The number of IL-13Rs were calcu-
lated as 39,700 (MDA-MB-231 2 clone 3) and 37,740
(PANC-1 2 clone 2) IL-13 molecules bound per cell.
Since IL-13 binding sites on vector only transfected cells
Figure 1. RT-PCR analysis for IL-13 receptor transcripts in MDA-
MB-231 and PANC-1 cell lines. Total RNA (2  g) from cells transfected
with or without IL-13R 2 chain or vector alone was examined for ex-
pression of mRNA for IL-13R 2 and IL-13R 1 chains by RT-PCR
analysis. The same amount of total RNA from PM-RCC cells served as a
positive control.
Figure 2. IL-13 binding to MDA-MB-231 and PANC-1 cells. Bind-
ing of 125[I]-labeled IL-13 was performed as described in Materials and
Methods. (A) Single-point binding assays on cells stably transfected with
vector-only or IL-13R 2 chain. Data were obtained from the mean of
duplicate determinations, and the assay was repeated several times. Cells
(5   105) were incubated at 4 C for 2 h with 200 pM 125[I]-labeled IL-13
with or without 40 nM unlabeled IL-4 or IL-13. Data are means; bars,
SD. The displacement curve (B) and Scatchard analysis (C) were gener-
ated from the binding data from MDA-MB-231 ( 2 clone 3) and
PANC-1 ( 2 clone 2) cells using LIGAND program (reference 35).1746 Gene Transfer of IL-13R 2 Chain Inhibits Tumorigenicity In Vivo
were calculated to be 90 (MDA-MB-231) and 160
(PANC-1) per cell, an increase in IL-13 binding sites in IL-
13R 2 chain transfectants was  440-fold and 240-fold
higher compared with control cells, respectively.
In Vitro Growth Characteristics and Stability of IL-13R 2
Chain Expression in Transfected Cells. To determine the ef-
fect of IL-13R 2 chain on in vitro cell growth characteris-
tics of MDA-MB-231 and PANC-1 cells, vector alone and
IL-13R 2 chain transfected cloned cells were cultured in
petri dishes and viable cell number determined at various
time points. As shown in Fig. 3, three clones each of both
MDA-MB-231 and PANC-1 cell lines grew in a similar
manner in vitro. There was no difference in growth rate
between vector only transfected control cells and IL-
13R 2 chain transfected cells.
To determine the in vitro stability of gene expression,
we cultured vector only transfected control cells and IL-
13R 2 chain transfected cells (MDA-MB-231 2 clone 3
and PANC-1 2 clone 2) for a 90-d period after removal
of antibiotics. During the culture, cells were split twice
(MDA-MB-231) or once (PANC-1) a week. At various
time points, total RNA was extracted and mRNA expres-
sion for IL-13R 2 chain was assessed by RT-PCR. In
MDA-MB-231 2 clone, IL-13R 2 gene expression de-
creased in a time-dependent manner, and on day 90 very
faint mRNA expression was detected (Fig. 4 A). However,
in case of PANC-1 2 clone, IL-13R 2 chain expression
remained at high level until day 90, suggesting this clone
expresses this chain very stably.
To further confirm the expression of IL-13R 2 chain
on plasma membranes of cells transfected with this chain,
we used a chimeric protein composed of IL-13 and a trun-
cated form of PE, IL-13 toxin (IL-13-PE38QQR). This
molecule was found to be potently cytotoxic to IL-13R-
positive solid tumor cells (30, 31, 38–40). It has been found
that IL-13 toxin will only bind and be cytotoxic to cells
that express high levels of IL-13R on cell surface. As
shown in Fig. 4 B, just after removal of antibiotic, in both
MDA-MB-231 and PANC-1 cells, cytotoxic activity of
IL-13 toxin dramatically increased after gene transfer of IL-
13R 2 chain. IC50 (the protein concentration required for
the inhibition of protein synthesis by 50%) in MDA-MB-
Figure 3. In vitro cell growth of MDA-MB-231 and PANC-1 tumor
cell clones. To examine in vitro cell growth of MDA-MB-231 and
PANC-1 cells transfected with IL-13R 2 chain or vector alone, cloned
cells (2   105) were cultured in 100-mm petri dishes and were harvested
by trypsin after 0–96 h, and then cell number was counted by Trypan
blue staining. The results were represented as means   SD of triplicate
determinations, and the assay was repeated several times.
Figure 4. In vitro stability of
IL-13R 2 chain expression on
MDA-MB-231 and PANC-1
clones. (A) Total RNA (2  g)
extracted from cells transfected
with IL-13R 2 chain or vector
alone at various time point after
removal of antibiotic was ex-
amined for the expression of
IL-13R 2 chain mRNA by
RT-PCR analysis. The same
amount of total RNA from PM-
RCC cells served as a positive
control. (B and C) After removal
of antibiotic (B, day 0 and C,
days 0–90), cells transfected with
IL-13R 2 chain or vector only
were cultured with various con-
centrations of IL-13-PE38QQR
(0–1,000 ng/ml) with or without
IL-4 or IL-13 (2  g/ml). The re-
sults were represented as means  
SD (n   4). The concentration
of IL-13-PE38QQR causing 50%
inhibition of protein synthesis
was calculated (IC50).1747 Kawakami et al.
231 and PANC-1 cell lines decreased from  1,000 ng/ml
to 0.25 ng/ml and from 60 ng/ml to  0.1 ng/ml, respec-
tively. These cytotoxic activities in cells transfected with
IL-13R 2 chain were neutralized by IL-13 not by IL-4,
indicating the cytotoxicity mediated by IL-13 toxin is spe-
cific. The stability of IL-13R 2 chain expression in MDA-
MB-231 and PANC-1 cells transfected with this chain was
also assessed by determining cytotoxicity mediated by IL-
13 toxin using cells cultured for same period as Fig. 4 A. As
shown in Fig. 4 C, IC50s increased in a time-dependent
manner in MDA-MB-231 cells transfected with IL-13R 2
chain. However, IC50 remained significantly lower than
observed in vector only transfected cells (Fig. 4 B). On day
90, the IC50 increased to  75 ng/ml correlating with sig-
nificant decrease in IL-13R 2 gene expression. On the
other hand, PANC-1 cells transfected with IL-13R 2
chain maintained high sensitivity to IL-13 toxin through-
out the 90-d period ( 1 ng/ml). These results were consis-
tent with RT-PCR results (Fig. 4 A), suggesting that the
transgene expression in PANC-1 cells transfected with IL-
13R 2 chain remained much stable than MDA-MB-231
transfectants. After 90 d of culture, both cell lines main-
tained their rapid growth characteristics as observed on day
0 (data not shown).
Overexpression of IL-13R 2 Chain on the Cell Surface In-
hibits Tumorigenicity of MDA-MB-231 and PANC-1 Tu-
mors. To investigate in vivo growth characteristics of
breast and pancreatic tumor cells that overexpress IL-
13R 2 chain, MDA-MB-231 and PANC-1 cell clones
transfected with IL-13R 2 chain or vector alone were im-
planted subcutaneously into the flank of nude mice. As
shown in Fig. 5 A, MDA-MB-231 vector only transfected
control tumor cells grew rapidly requiring sacrifice of these
animals between days 44 and 50 because of heavy tumor
burden. MDA-MB-231 tumors expressing IL-13R 2
chain also started growing as fast as control tumors initially;
however, they stopped growing completely and tumor re-
mained same in size ( 20 mm2) until days 40–46. After
that, they started growing again gradually and reached the
size of 160–220 mm2 on day 70–82. In additional experi-
ments, cells derived from different IL-13R 2 chain-
expressing clones grew into tumors at a similar slower pace
compared with control cells (data not shown). On the
other hand, despite linear tumor growth of PANC-1 vec-
tor only transfected control cells, PANC-1 tumors express-
ing IL-13R 2 chain stopped growing after they established
as palpable tumors between days 3 and 5. Then, these tu-
mors started diminishing. Between days 11 and 16, almost
all the tumors disappeared completely. Between days 21
and 32, some animals had palpable tumors (1/5 mice of
clone 1, 2/5 mice of clone 2, and 1/5 mice of clone 3),
however, they never grew beyond the size of 20 mm2.
To assess the in vivo stability of IL-13R 2 chain expres-
sion, MDA-MB-231 and PANC-1 tumors were resected at
various time points (MDA-MB-231, days 14, 53, and 90)
or on day 90 (PANC-1; vector only transfected control and
IL-13R 2 chain transfected clones that had very small tu-
mors). Tumors were minced and treated with 10  g/ml
collagenase, 1 mg/ml hyaluronidase, and 0.5 mg/ml DNase
(Sigma-Aldrich), washed with PBS for two times and cul-
tured in culture medium containing 10% FBS. After three
passages, contaminating tumor debris and blood cells were
removed, and then total RNA was extracted and mRNA
expression for IL-13R 2 chain was assessed by RT-PCR.
As shown in Fig. 5 B, in MDA-MB-231 tumors derived
from IL-13R 2 chain transfected clone 3, the expression
Figure 5. In vivo MDA-MB-231 and PANC-1 tumor growth and stability of IL-13R 2 chain expression. (A) Nude mice were implanted subcutane-
ously with 5   106 MDA-MB-231 or 4   106 PANC-1 cloned cells on day 0. Palpable tumors developed within 3–4 d. The results were represented as
means   SD (n   5). (B and C) Tumors were resected from mice on days 14, 53, and 90 (MDA-MB-231) or day 90 (PANC-1), then tumors were
minced and cells were cultured for three passages. (B) Total RNA was extracted and mRNA expression for IL-13R 2 chain was assessed by RT-PCR.
(C) Cells were cultured with various concentrations of IL-13-PE38QQR (0–1,000 ng/ml) and protein synthesis inhibition assays were performed, and
the concentration of IL-13-PE38QQR at which IC50 occurred was calculated. The results were represented as means   SD (n   4).1748 Gene Transfer of IL-13R 2 Chain Inhibits Tumorigenicity In Vivo
level of IL-13R 2 chain mRNA was found to be de-
creased in a time-dependent manner with almost complete
disappearance on day 90. Whereas all the clones derived
from PANC-1 tumors on day 90 showed no or very low
level expression of IL-13R 2 chain.
To further analyze the IL-13R 2 chain expression on
resected tumors, using three-passage-cultured cells, cyto-
toxic activity of IL-13 toxin was examined. As shown in
Fig. 5 C, cells derived from MDA-MB-231 tumors (IL-
13R 2 chain transfectants clone 3) showed the decreasing
sensitivities to IL-13 toxin in a time-dependent manner.
On day 90, when IL-13R 2 gene expression was signifi-
cantly diminished, the IC50 rose to  250 ng/ml. The IC50
still remained at least four times lower compared with
vector only transfected control cells (IC50   1,000 ng/
ml). Cells cultured from PANC-1 IL-13R 2 chain trans-
fected clones-derived tumors on day 90 showed signifi-
cantly less sensitivity to IL-13 toxin compared with in
vitro cultured PANC-1 IL-13R 2 chain transfected cells
(IC50   1 ng/ml; Fig. 4 C), and the IC50 ranged between
27 and 42 ng/ml. Sensitivity of PANC-1 cells cultured
from vector only transfected control clone-derived tumor
to IL-13 toxin was similar to IL-13R 2 chain transfected
clones-derived tumors (IC50   45 ng/ml). These results
were consistent with RT-PCR results and indicate that
loss of IL-13R 2 chain in vivo correlated with loss in
sensitivity to IL-13 toxin.
Infiltration of Inflammatory Cells Was Observed at Early
Time Point After Implantation of MDA-MB-231 Tumors
Overexpressing IL-13R 2 Chain. To investigate the
mechanism by which tumorigenicity of IL-13R 2 chain
transfected tumors was inhibited, both vector-only trans-
fected and IL-13R 2 chain transfected MDA-MB-231 tu-
mors were resected from mice on days 3, 5, 8, and 35 after
the implantation, and then histological study of the tumor
was performed after H&E staining. As shown in Fig. 6 A,
vector-only transfected control cells developed breast tu-
mors without infiltration of inflammatory cells. On the
other hand, MDA-MB-231 tumor transfected with IL-
13R 2 chain displayed a marked cellularity (Fig. 6 B and
C). The cell infiltration was dominant in connective tissue
around the tumor on day 3, however, as the time pro-
gressed (days 5 and 8), inflammatory cells were observed
infiltrating inside the tumor mass. Both vector-only and
IL-13R 2 chain transfected tumors resected on day 35 dis-
played limited level of inflammatory cells. PANC-1 tumors
could not be analyzed on days 8 and 35 because tumor had
completely regressed. The population of infiltrating cells
differed among tumors, and neutrophils were determined
to be dominant cell type (Table I).
Immunofluorescence Assays Showed Production of IL-13 from
Neutrophils in IL-13R 2 Chain Overexpressing Tumors. To
further characterize the infiltrating cells, immunofluores-
cence assays were performed on frozen tissue sections ob-
Figure 6. MDA-MB-231 tumors overexpressing IL-13R 2 chain display cellular infiltration. MDA-MB-231 tumors originated from clones trans-
fected with vector alone (A) or IL-13R 2 chain (B and C) were resected from mice on day 3, 5, 8, and 35 after the implantation, and then histological
study of the tumor was performed by H&E staining (B, original magnification:   200 and C, original magnification:  400). Picture C shows the higher
power view of squared area in B.1749 Kawakami et al.
tained from subcutaneously growing MDA-MB-231 IL-
13R 2 overexpressing tumors. As shown in Fig. 7, staining
with antibody to IL-13 (C-19, Fig. 7 A), neutrophils (Gr-1,
Fig. 7 B) and macrophages (Mac-3, data not shown) in
IL-13R 2 chain transfected tumors on day 5 showed infil-
tration of cells that produce IL-13. On the other hand,
mock-transfected control tumors and IL-13R 2–trans-
fected tumors after 35 d of growth did not show detectable
levels of staining for IL-13, neutrophils, or macrophages
(data not shown). Interestingly, we found colocalization of
IL-13 and neutrophils but not macrophages which indi-
cates that IL-13 is produced from neutrophils (Fig. 7 D).
On the other hand, macrophages did not produce IL-13.
These results suggest that infiltrating neutrophils are most
probably involved in the inhibition of tumorigenicity by
gene transfer of IL-13R 2 chain.
IL-13 Showed Modest Antitumor Activity in IL-13R 2
Chain Overexpressing Tumors In Vitro and In Vivo. Be-
cause IL-13 production from neutrophils was observed in
IL-13R 2 overexpressing tumors, we hypothesized that
IL-13 itself may have direct antitumor effect or is involved
in the inhibition of tumorigenicity. To address this issue,
we first performed in vitro colony formation assay in
MDA-MB-231 and PANC-1 cells transfected with vector
Table I. Population of Infiltrating Cells as Determined by Histological Examination
Time (d) Control IL-13R 2 chain transfectants
Lymphocytes Macrophages Neutrophils
MDA-MB-231
Day 3    a     
Day 5          
Day 8       
Day 35       
PANC-1
Day 5       
aInfiltrating cells observed in day 3 tumors were mainly in the connective tissue around the tumor section.
++, moderate; +, mild;  , not detectable.
Figure 7. Immunofluorescence
assay on IL-13R 2 chain overex-
pressing MDA-MB-231 tumors.
Immunofluorescence assays using
Abs for IL-13 (C-19, A) or neutro-
phils (Gr-1, B) were performed on
frozen tissue sections on tumors re-
sected on day 5 after subcutaneous
implantation of MDA-MB-231
cells. (C) Phase contrast. (D) Super-
imposed image of A and B. Original
magnification:  400.1750 Gene Transfer of IL-13R 2 Chain Inhibits Tumorigenicity In Vivo
only (mock control) or IL-13R 2 chain. As shown in Fig.
8 A, in both cell lines, IL-13 showed a modest inhibitory
effect on colony formation in IL-13R 2 transfectants (50%
inhibition in MDA-MB-231 cells and 28% inhibition in
PANC-1 cells at 50–500 ng/ml of IL-13). Although IL-13
showed slight inhibitory effect on colony formation in
mock control MDA-MB-231 cells, the effect was more
pronounced in IL-13R 2 transfectants.
To assess in vivo antitumor effect of IL-13 in IL-13R 2
overexpressing tumors, we then directly injected IL-13 (1
 g) in MDA-MB-231 tumor (mock control and IL-
13R 2 transfectants) bearing nude mice intratumorally
from days 4 to 8 (total five injections). As shown in Fig. 8
B, in control tumors, IL-13 did not show significant effect
and tumors grew as fast as tumors without any IL-13 injec-
tions (Fig. 5 A). On the other hand, in IL-13Ra2 overex-
pressing tumors, IL-13 induced regression of tumors during
the injection period, and two out of five tumors were com-
pletely disappeared by day 33. Although in the rest of the
mice tumors started growing eventually, the mean size of
the tumors remained very small (28 mm2) compared with
excipient-injected control tumors (207 mm2) by day 83 af-
ter implantation of the tumors. These results suggest that
IL-13 produced by neutrophils should be considered to
play a role in the inhibition of tumorigenesis in vivo in IL-
13R 2 chain overexpressing tumors.
Depletion of Neutrophils in IL-13R 2 Chain Overexpressing
Tumor Bearing Nude Mice Showed Initial Growth of Tumors.
To assess whether neutrophils by itself may have some po-
tential role in the inhibition of tumor growth, we depleted
neutrophil in nude mice by intraperitoneal injections of
antineutrophil antibody (Gr-1) and IL-13R 2 chain trans-
fected MDA-MB-231 cells were implanted. During the
injection period, blood samples were taken from mice and
absence of neutrophils was confirmed (data not shown).
As shown in Fig. 9, during the depletion period IL-
13R 2 chain transfected tumor grew better than excipi-
ent-only injected tumors. These tumors kept on growing
by day 14 after implantation, then began to regress once
antibody injection was stopped. Finally, these tumors re-
gressed to the mean tumor size of control IL-13R 2 tu-
mors (20–23 mm2) when the experiment was terminated.
These data indicate that neutrophils play a partial role in
the inhibition of tumor growth.
High Levels of IL-8 Was Constitutively Released from IL-
13R 2 Chain Overexpressing MDA-MB-231 Tumor Cells.
IL-8 has been shown to have potent antitumor effect in
several tumor types including lung cancer, ovarian cancer,
and prostate cancer (20, 21). To explore whether this
chemokine is released from IL-13R 2 chain overexpressing
tumor cells, we extracted RNA from MDA-MB-231 cells
transfected with vector only (mock control) or IL-13R 2
chain after treatment with IL-13 (50 ng/ml) for 24 h. By
serial twofold dilutions of RNA samples, we found that
IL-8 gene is constitutively expressed in MDA-MB-231
mock control cells, and approximately fourfold upregulation
of this gene was observed after stimulation with IL-13 (Fig.
10 A). To our surprise, in IL-13R 2 chain transfected MDA-
MB-231 cells, IL-8 gene expression was two- to fourfold
higher compared with mock control cells. To further con-
firm these results, we performed ELISA assays for human
Figure 8. Antitumor activity of IL-13 in IL-13R 2 chain overexpress-
ing tumors in vitro and in vivo. (A) Vector-only or IL-13R 2 chain trans-
fected cells (500 cells per group) were allowed to adhere in Petri dishes,
and the medium was replaced with medium containing various concentra-
tions (0–500 ng/ml) of IL-13. Cells were cultured for 9 d, and colonies
consisting of at least 50 cells were scored after staining with crystal violet.
Data are means of triplicate determinations; bars, SD. (B) Vector-only or
IL-13R 2 chain transfected MDA-MB-231 cells (5   106) were im-
planted in the flank of nude mice on day 0 and were treated with intratu-
moral administration of either excipient or IL-13 (1  g) from days 4 to 8
(total five injections). The results were represented as means   SD (n   5).
Figure 9. Administration of the antibody to neutrophil in nude mice
enhances the tumor growth of IL-13R 2 chain overexpressing tumor.
Vector-only or IL-13R 2 chain transfected MDA-MB-231 cells (5  
106) were implanted in the flank of nude mice on day 0 and were treated
with intraperitoneal administration of either excipient or Gr-1 (0.1 mg)
on days  1, 1, 4, and 8 (total four injections). The results were repre-
sented as means   SD (n   5).1751 Kawakami et al.
IL-8 in MDA-MB-231 derived culture supernatants. As
shown in Fig. 10 B, after stimulation with IL-13 (50 ng/
ml), IL-8 production from the mock control cells was in-
creased in a time-dependent manner. In IL-13R 2 chain
transfected MDA-MB-231 cells, constitutive release of IL-8
was  1.75-fold higher compared with mock control cells.
IL-8 release level from IL-13R 2 chain transfectants was
also augmented in a time-dependent manner. These results
suggest that IL-8 is constitutively produced from IL-13R 2
chain overexpressing tumor cells and this production level
is upregulated after stimulation with IL-13.
Discussion
In this study, we demonstrate that overexpression of IL-
13R 2 chain inhibits tumorigenicity of human breast and
pancreatic tumor cells in nude mice. Although there was
no difference in growth between vector only transfected
cells and IL-13R 2 chain transfected cells in vitro, in nude
mice, tumorigenicity was impaired in IL-13R 2 chain
overexpressing tumors. The presence of inflammatory cells,
particularly neutrophils were found to correlate with the
lack of tumorigenicity or significant reduction in tumor
growth rate. Neutrophils were found to produce IL-13 and
IL-13 had modest antitumor effect in IL-13R 2 overex-
pressing tumors. Moreover, IL-13R 2 overexpressing tu-
mor cells produced high level of IL-8 which has been
shown to reduce tumorigenicity in several tumor models.
To our knowledge this is the first report that implicates cy-
tokine receptor chain in tumorigenesis.
It is of interest to note that stability of IL-13R 2 chain
expression and tumor growth in nude mice correlated ex-
tremely well. MDA-MB-231 tumors transfected with IL-
13R 2 chain did not begin to grow until  day 50, after
which they grew gradually. This dormancy and growth of
tumors in vivo correlated with IL-13R 2 chain expression
in vitro and in vivo. MDA-MB-231 cells transfected with
IL-13R 2 chain showed decrease in IL-13R 2 gene ex-
pression in a time-dependent manner in vitro. Similarly
gene expression decreased disappearing completely on day
90 in vivo. The decrease in gene expression was further
confirmed by cytotoxicity assay. IL-13-PE38QQR was
highly cytotoxic to MDA-MB-231 IL-13R 2 overex-
pressing cells initially. However, as the gene expression de-
creased, the cytotoxicity decreased. This decrease in cyto-
toxicity was evident in vitro–cultured cells and on tumor
cells obtained from in vivo–growing tumors. In contrast to
MDA-MB-231cells, PANC-1 tumor cell clones trans-
fected with IL-13R 2 chain showed very limited growth
in nude mice, which was consistent with in vitro strong
expression of this chain throughout 90-d culture. How-
ever, when residual tumor was harvested on day 90, no de-
tectable expression of IL-13R 2 chain was observed as
assessed by RT-PCR and IL-13-PE38QQR–mediated cy-
totoxic assays. Since pancreatic tumor cells transfected with
IL-13R 2 chain did not form tumors, earlier time points
could not be evaluated for the expression of IL-13R 2
gene. It is possible that IL-13R 2 gene was lost in last
few days of tumor growth. These results suggest that in
general, presence of IL-13R 2 chain in MDA-MB-231
and PANC-1 tumor cells controls and prevents tumor
growth. When cells loose this receptor chain, they acquire
tumorigenicity in nude mice.
To reveal the mechanism by which IL-13R 2 chain in-
hibited tumorigenicity in MDA-MB-231 and PANC-1
tumors, we performed histological examinations and im-
munofluorescence assays. We observed infiltration of in-
flammatory cells, particularly neutrophils and macrophages
during early period of slow tumor growth suggesting that
these cells may play an important role in the inhibition of
tumorigenicity caused by overexpression of IL-13R 2
chain. Moreover, we found that infiltrated neutrophils
produced IL-13 that had modest antitumor effect on IL-
13R 2 chain overexpressing tumor in vitro and in vivo.
IL-13 has been shown to be produced by B cells, T cells,
and monocytes (41). Infiltrating inflammatory cells also
produce Th2 cytokines (42, 43). In addition IL-13 has
been shown to inhibit in vitro growth of renal cell carci-
Figure 10. IL-8 production from MDA-MB-231 cells transfected with
vector only or IL-13R 2 chain. (A) Total RNA was extracted from
MDA-MB-231 cells transfected with vector only (mock control) or IL-
13R 2 chain after treatment with IL-13 (50 ng/ml) for 24 h. Then IL-8
and GAPDH mRNA levels in serial twofold dilutions of RNA were
measured by RT-PCR. GAPDH mRNA was measured to normalize the
amount of mRNA in each group. (B) after stimulation with IL-13 (50
ng/ml) at various time periods (0–72 h), culture supernatant from MDA-
MB-231 cells (5   105 cells each in 6-well plates; mock control and IL-
13R 2 transfectants) were collected and applied to ELISA plate to assess
IL-8 production. The results were represented as means   SD (n   3).1752 Gene Transfer of IL-13R 2 Chain Inhibits Tumorigenicity In Vivo
noma and breast tumor cells (44, 45). Gene transfer of IL-
13 in tumor cells has been shown to inhibit tumorigenicity
of mastocytoma cells in animal model (22). Thus, these re-
ports support our findings that IL-13 secreted by infiltrat-
ing inflammatory cells may at least partially inhibit tumor
growth of IL-13R 2 chain overexpressing tumors. We
also observed rapid initial growth of IL-13R 2 chain
transfected tumor in neutrophil depleted mice similar to
control mice, and when administration of antineutrophil
antibody stopped, the tumor growth decreased similar to
nonneutrophil depleted mice. Because neutrophils, partic-
ularly polymorphonuclear leukocytes are known to en-
hance antitumor immune responses against cancers (23,
46, 47), neutrophils along with IL-13 may play some role
in the inhibition of growth of IL-13R 2 chain overex-
pressing tumors. Alternatively, IL-13 produced by neutro-
phils may induce additional factor(s) from tumor cells that
may further inhibit tumor growth of IL-13R 2 chain
overexpressing tumors.
We found high level of IL-8 production from IL-13R 2
chain overexpressing MDA-MB-231 cells. IL-8 has been
shown to regulate angiogenesis and matrix metalloprotein-
ase 9 (MMP-9) productions in tumors consequently reduc-
ing tumorigenicity and metastatic potential (20, 21). It is
therefore possible that IL-8 secreted by IL-13R 2 chain
overexpressing tumor cells results in the regulation of tu-
morigenicity. However, Arenberg et al. observed that by in-
jecting neutralizing antibody to IL-8 in SCID mice results
in regression of non-small cell lung cancer tumor xe-
nografts (26). Thus, IL-8 can produce contrasting effect in
different tumor models. In our RT-PCR and ELISA re-
sults, IL-13 was found to further augment IL-8 expression
in IL-13R 2 transfected tumors. Taken together, our re-
sults suggest that the mechanism involved in the loss of in
vivo tumorigenicity of IL-13R 2 chain overexpressing tu-
mor cells involve infiltration of IL-13 producing neutro-
phils which in turn augment IL-8 production from tumor
cells for an autocrine growth inhibition.
Although there seems to be no reports that show inhibi-
tion of tumorigenicity by overexpression of one cytokine
receptor subunit on the cell surface, it has been reported
that some cell-surface antigens, e.g., a proliferation-induc-
ing ligand (APRIL), heregulin (HRG), and transforming
growth factor   inhibit tumorigenesis in certain types of
cancers (48–50). Furthermore, cytokines like IL-4, IL-8,
and IL-13 produced by inflammatory cells such as neutro-
phils, macrophages, and/or eosinophils have been shown
to inhibit tumorigenesis (20–22, 24, 25, 42). Our results
also suggest involvement of infiltrating inflammatory cells
in the inhibition of tumorigenesis caused by IL-13R 2
chain overexpression. In our previous studies, we gener-
ated several IL-13R 2 chain transfected cancer cell clones
including head and neck and prostate cancer cells, how-
ever, in vivo tumorigenicity was not impaired in these
cases (31, 40). Because IL-13R 2 chain expression level
was lower in these cases, it is possible that the loss of tu-
morigenicity by IL-13R 2 chain overexpression depends
on the IL-13R 2 expression level. Alternatively, various
tumor types behave differently. These possibilities are be-
ing investigated.
The significance of constitutive expression of IL-13R 2
chain in certain tumor cell types is still not known. In mu-
rine model, extracellular domain of IL-13R 2 chain is se-
creted by cells and has been detected in serum and urine of
mice. However, extracellular domain of this chain has not
been detected in body fluids of humans (12). Based on mu-
rine studies it has been proposed that extracellular domain
of IL-13R 2 chain serves as a decoy and possibly a IL-13
carrier protein. In contrast, here we show a unique func-
tion of IL-13R 2 chain which inhibits tumorigenicity of
breast and pancreatic tumor cells. We hypothesize that IL-
13R 2 chain may control vigorous growth of tumor cells
in vivo. Tumor cells may grow faster if level of expression
was decreased or this chain was not expressed at all. Alter-
natively, constitutive expression of IL-13R 2 chain in tu-
mor cells may recruit Th2 cells that predominantly produce
IL-13, which may help escape immune surveillance and tu-
mor development in immunocompetent hosts. Additional
studies are warranted to further unravel the mechanism of
inhibition of tumor growth and exact function of IL-
13R 2 chain in the context of tumor biology.
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